Hoff PM, Ansari R, Batist G et al (2017) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292. https://doi.org/10.1200/jco.2001.19.8.2282

Article  Google Scholar 

Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338. https://doi.org/10.1038/nrc1074

Article  CAS  PubMed  Google Scholar 

Meulendijks D, Cats A, Beijnen JH, Schellens JHM (2016) Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity–ready for clinical practice? Cancer Treat Rev 50:23–34. https://doi.org/10.1016/j.ctrv.2016.08.002

Article  CAS  PubMed  Google Scholar 

Sharma BB, Rai K, Blunt H et al (2021) Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 26:1008–1016. https://doi.org/10.1002/onco.13967

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Cutsem BE, Twelves C, Cassidy J et al (2010) Fluorouracil plus leucovorin in patients with metastatic colorectal cancer : results of a large phase III study. J Clin Oncol 19:4097–4106

Article  Google Scholar 

Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215–237. https://doi.org/10.2165/00003088-198916040-00002

Article  CAS  PubMed  Google Scholar 

Henricks LM, Lunenburg CATC, Meulendijks D et al (2015) Translating DPYD genotype into DPD phenotype: Using the DPYD gene activity score. Pharmacogenomics 16:1277–1286. https://doi.org/10.2217/PGS.15.70

Article  CAS  PubMed  Google Scholar 

Meulendijks D, Henricks LM, Sonke GS et al (2015) Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:1639–1650. https://doi.org/10.1016/S1470-2045(15)00286-7

Article  CAS  PubMed  Google Scholar 

Deenen MJ, Meulendijks D, Cats A et al (2016) Upfront genotyping of DPYD∗2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34:227–234. https://doi.org/10.1200/JCO.2015.63.1325

Article  CAS  PubMed  Google Scholar 

Henricks LM, Lunenburg CATC, de Man FM et al (2018) DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2045:1459–1467. https://doi.org/10.1016/S1470-2045(18)30686-7

Article  Google Scholar 

Meulendijks D, Henricks LM, Jacobs BAW et al (2017) Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 116:1415–1424. https://doi.org/10.1038/bjc.2017.94

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sistonen J, Büchel B, Froehlich TK et al (2014) Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics 15:1653–1666. https://doi.org/10.2217/pgs.14.126

Article  CAS  PubMed  Google Scholar 

Knikman JE, Gelderblom H, Beijnen JH et al (2021) Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther 109:591–604. https://doi.org/10.1002/cpt.2069

Article  CAS  PubMed  Google Scholar 

Jiang H, Lu J, Ji J (2004) Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 141:616–623. https://doi.org/10.1038/sj.bjp.0705651

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boisdron-Celle M, Remaud G, Traore S et al (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271–282. https://doi.org/10.1016/j.canlet.2006.09.006

Article  CAS  PubMed  Google Scholar 

Etienne-Grimaldi MC, Boyer JC, Beroud C et al (2017) New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE 12:1–19. https://doi.org/10.1371/journal.pone.0175998

Article  CAS  Google Scholar 

With M, Knikman J, Man FM et al (2022) Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin Pharmacol Ther 112:62–68. https://doi.org/10.1002/cpt.2608

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henricks LM, Jacobs BAW, Meulendijks D et al (2018) Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.13719

Article  PubMed  PubMed Central  Google Scholar 

Thomas F, Maillard M, Launay M et al (2021) Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation. Ann Oncol 32:810–811. https://doi.org/10.1016/j.annonc.2021.02.020

Article  CAS  PubMed  Google Scholar 

Carriat L, Quaranta S, Solas C et al (2022) Renal impairment and DPD testing: Watch out for false-positive results! Br J Clin Pharmacol. https://doi.org/10.1111/bcp.15482

Article  PubMed  Google Scholar 

Gaible C, Narjoz C, Loriot MA et al (2021) Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results. Cancer Chemother Pharmacol 88:1049–1053. https://doi.org/10.1007/s00280-021-04354-7

Article  CAS  PubMed  Google Scholar 

Jacobs BAW, Rosing H, de Vries N et al (2016) Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. J Pharm Biomed Anal 126:75–82. https://doi.org/10.1016/j.jpba.2016.04.039

Article  CAS  PubMed  Google Scholar 

Coudoré F, Roche D, Lefeuvre S et al (2012) Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma. J Chromatogr Sci 50:877–884. https://doi.org/10.1093/chromsci/bms085

Article  CAS  PubMed  Google Scholar 

van den Wildenberg SAH, Streng AS, van den Broek R et al (2022) Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions. J Pharm Biomed Anal. https://doi.org/10.1016/j.jpba.2022.115027

Article  PubMed  Google Scholar 

Capiau S, van Landschoot A, Reyns T, Stepman H (2022) Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma. Clin Chem Lab Med 60:E112–E115

Article  CAS  PubMed  Google Scholar 

César IC, Cunha-Júnior GF, Duarte Byrro RM et al (2012) A rapid HPLC-ESI-MS/MS method for determination of dihydrouracil/uracil ratio in plasma: evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer. Ther Drug Monit 34:59–66. https://doi.org/10.1097/FTD.0b013e318240405f

Article  CAS  PubMed  Google Scholar 

Casneuf V, Borbath I, van den Eynde M et al (2021) Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta Clinica Belgica: Int J Clin Lab Med. https://doi.org/10.1080/17843286.2020.1870855

Article  Google Scholar 

Haute Autorité de S (2018) Des recommandations pour prévenir certaines toxicités sévères des chimiothérapies par fluoropyrimidines

Maillard M, Launay M, Royer B et al (2022) Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.15536

Article  PubMed  Google Scholar 

R Core Team (2020) (2020) R: A language and environment for statistical computing

European Medicines Agency (2020) EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine 31:3

Google Scholar 

Tybirk L, Hoffmann-Lücke E, Greibe E (2023) Instability of uracil in whole blood might affect cancer treatment with fluoropyrimidines. Clin Chim Acta 538:87–90. https://doi.org/10.1016/j.cca.2022.10.017

Article  CAS  PubMed  Google Scholar